Evidence map›Paper›PMID 39342599›Full record

ArticleAsian Pacific journal of cancer prevention : APJCP2024

Development and Validation of a Prognostic Nomogram Model for HER2-Positive Male Breast Cancer Patients.

Lifeng Zhao, Ziren Lin, Shitang Nong, Caixin Li, Junnan Li, Cheng Lin, Sher Zaman Safi, Shiqing Huang, Ikram Shah Bin Ismail

Abstract readValidation Study
PubMed Full text at PMC Publisher
In one paragraph

Article in Asian Pacific journal of cancer prevention : APJCP, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Lifeng ZhaoAffiliated Hospital of Youjiang Medical University for Nationalities, Baise, 533000, China.
Ziren LinThe People's Hospital of Baise, Baise, 533000, China.
Shitang NongThe People's Hospital of Baise, Baise, 533000, China.
Caixin LiYoujiang Medical University for Nationalities, Baise, 533000, China.
Junnan LiAffiliated Hospital of Youjiang Medical University for Nationalities, Baise, 533000, China.
Cheng LinAffiliated Hospital of Youjiang Medical University for Nationalities, Baise, 533000, China.
Sher Zaman SafiFaculty of Medicine, Bioscience and Nursing, MAHSA University, Bandar Saujana Putra, Jenjarom 42610, Malaysia.
Shiqing HuangAffiliated Hospital of Youjiang Medical University for Nationalities, Baise, 533000, China.
Ikram Shah Bin IsmailFaculty of Medicine, Bioscience and Nursing, MAHSA University, Bandar Saujana Putra, Jenjarom 42610, Malaysia.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundHER2-positive male breast cancer (MBC) is a rare condition that has a poor prognosis. The purpose of this study was to establish a nomogram model for predicting the prognosis of HER2-positive MBC patients.

methods240 HER2-positive MBC patients from 2004 to 2015 were retrieved from the surveillance, epidemiology, and end results (SEER) database. All HER2-positive MBC patients were divided randomly into training (n = 144) and validation cohorts (n = 96) according to a ratio of 6:4. Univariate and multivariate Cox regression analyses were used to determine the prognostic factors associated with HER2-positive MBC patients. A clinical prediction model was constructed to predict the overall survival of these patients. The nomogram model was assessed by using receiver operating characteristics (ROC) curves, calibration plots and decision curve analysis (DCA).

resultsThe Cox regression analysis showed that T-stage, M-stage, surgery and chemotherapy were independent risk factors for the prognosis of HER2-positive MBC patients. The model could also accurately predict the Overall survival (OS) of the patients. In the training and validation cohorts, the C indexes of the OS nomograms were 0.746 (0.677-0.815) and 0.754 (0.679-0.829), respectively. Calibration curves and DCA verified the reliability and accuracy of the clinical prediction model.

conclusionIn conclusion, the predictive model constructed had good clinical utility and can help the clinician to select appropriate treatment strategies for HER2-positive MBC patients.

Indexed as

Breast Neoplasms, MaleErb-b2 Receptor Tyrosine KinasesNomogramsAdultAgedBiomarkers, TumorFollow-Up StudiesHumansMaleMiddle AgedPrognosisROC CurveSEER ProgramSurvival RateBiomarkers, TumorERBB2 protein, humanErb-b2 Receptor Tyrosine KinasesCox regressionHER2-positiveMale breast cancernomogramSEER database

Identifiers

PMID39342599
PMCPMC11700337

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.